

**INNOVATION VENTURES** 

**AVAILABLE TECHNOLOGIES** 

**CONTACT US** 

Request Information

Permalink

## Small Molecule Pcsk9 Inhibitors

Tech ID: 34403 / UC Case 2023-098-0

#### **TECHNOLOGY DESCRIPTION**

Therapeutic inhibition of PCSK9 lowers LDL cholesterol and reduces the risk of heart disease, even when added on top of maximum dose statin therapy. However, there are currently no FDA approved small molecule inhibitors for PCSK9. UCSF scientists engineered a cell-based, amplified readout of PCSK9 protease activity and translated this into a high-throughput screen. They have identified small molecules that bind to and allosterically affect PCSK9 processing, and upregulate the LDL receptor in model cell cultures, and which could be attractive therapies for further cholesterol lowering and the prevention of atherosclerosis.

#### STAGE OF DEVELOPMENT

proof of concept

#### PATENT STATUS

Patent Pending

# **CONTACT**

Catherine Smith

Catherine.Smith2@ucsf.edu tel: 510-646-0631.



### **OTHER INFORMATION**

#### **CATEGORIZED AS**

**▶** Biotechnology

▶ Health

**RELATED CASES** 

2023-098-0

**ADDRESS** 

**UCSF** 

**Innovation Ventures** 

600 16th St, Genentech Hall, S-272,

San Francisco, CA 94158

CONTACT

Tel:

innovation@ucsf.edu

https://innovation.ucsf.edu

Fax:

**CONNECT** 

Follow in Connect

© 2025, The Regents of the University of

California

Terms of use Privacy Notice